Payment & Shipping Terms:
|Product Name:||Lapatinib||Advantages:||Reship Policy|
|Type:||Pharmaceutical Intermediate||Appearance:||White Powder|
|Grade:||High Build And Good Leveling,Pharmaceutcial Grade|
Lapatinib (INN), used in the form of lapatinib ditosylate, (USAN) (Tykerb/Tyverb, GSK) is an orally active drug for breast cancer and other solid tumours. It is a dual tyrosine kinase inhibitor which interrupts the HER2/neu and epidermal growth factor receptor (EGFR) pathways. It is used in combination therapy for HER2-positive breast cancer. It is used for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 (ErbB2).
|Loss on drying||≤0.5%||0.12|
|Residue on lgnition||≤0.1%||0.03|
|Yeast and Mould||≤100 cfu/g||<000|
|Conclusion||Conforms with USP/EP standards|
Lapatinib is a cancer medicine that interferes with the growth and spread of cancer cells in the body.
Lapatinib is used to treat a certain type of hormone-related breast cancer that has progressed or spread after treatment with other cancer medicines.
In postmenopausal women, lapatinib is given in combination with a hormonal medicine called letrozole (Femara). In others, lapatinib is given together with a cancer medicine called capecitabine (Xeloda).
On March 13, 2007, the U.S. Food and Drug Administration (FDA) approved lapatinib in combination therapy for breast cancer patients already using capecitabine (Xeloda, Roche). In January 2010, Tykerb received accelerated approval for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the HER2 receptor and for whom hormonal therapy is indicated.
Pharmaceutical company GlaxoSmithKline (GSK) markets the drug under the propriety names Tykerb (mostly US) and Tyverb (mostly Europe). The drug currently has approval for sale and clinical use in the US, Australia, Bahrain, Kuwait, Venezuela, Brazil,New Zealand,South Korea, Switzerland, Japan, Jordan, the European Union, Lebanon, India and Pakistan.
On the 2nd of August 2013, India's Intellectual Property Appellate Board revoked the patent for Glaxo's Tykerb citing its derivative status, while upholding at the same time the original patent granted for Lapatinib.
The drug lapatinib ditosylate is classified as S/NM (a synthetic compound showing competitive inhibition of the natural product) that is naturally derived or inspired substrate (Gordon M. Cragg, Paul G. Grothaus, and David J. Newman, Impact of Natural Products on Developing New Anti-Cancer Agents, Chem. Rev. 2009, 109, 3012–3043)
other product :
|Product Name||Cas No|
we, Yihan Industrial Co., Ltd from china are specilized in steroids powder , semi-finished liquids , peptides , Sarm powder,HGH,HCG,Finished Liquid and other pharmaceutical materials for many years .
If you have any further questions or need a sample,Please do not hesitate to contact me.Thank you!